Molecular diagnostic patents January to September 1999: part 1 - disease targets
Author: Harbron, S.
Source: Expert Opinion on Therapeutic Patents, Volume 9, Number 12, December 1999 , pp. 1611-1626(16)
Publisher: Informa Healthcare
Pharmacogenomic advances mean that simple prescribing of drugs will no longer be enough. Instead the genetic profile of the patient, which will determine his or her response to the available drugs, will need to be assessed. For example, a certain drug may have its most beneficial effect on patients with a particular genetic profile. The effect may be less potent on other patients, and the drug might have adverse side effects on yet further patients. By identifying the patient group that is most receptive to treatment with this drug, problems with low efficacy and side effects are circumvented. This could mean that some drugs that fail in present day clinical trials may find utility in the future for a small group of patients only. This targeted treatment will thus lead to more appropriate and more economic patient treatment. It is inevitable that the trend in drug administration will be toward combined Rx/Dx solutions, and in vitro diagnostics will become even more integrated into the disease management process. In addition, pharmaceutical companies are embracing pharmacogenomic and other molecular approaches to develop assays for use in high-throughput screening systems, so that the high numbers of hits are efficiently and economically converted into a rather smaller list of lead compounds. This internal market is estimated to be worth between US$1.5 and US$2 bn. Thus, molecular diagnostics has a dual role for the pharmaceutical industry. On the one hand there is a market for pharmacogenomic diagnostics for internal use in pharmaceutical companies, and on the other there will be the demand for combined Rx/Dx solutions. In this review, patent documents published between January and September 1999 by EPO, WIPO and US PTO and Japanese patents published in January and February 1999 have been analysed. The analysis has utilised the Diagnostics Insight database, which characterises documents according to whether they are concerned with infection, disease, analyte or enabling technology patents. Documents are further classified into nucleic acid (NA) based approaches (either using gene probes or amplification techniques) and immunoassay-based approaches.
Document Type: Miscellaneous
Affiliations: 44 Swing Gate Lane, Berkhamsted, Hertfordshire, HP4 2LL, UK. S.Harbron@experts.co.uk
Publication date: December 1, 1999